Many promising drug candidates often face de-prioritization due to financial constraints, strategic shifts, or resource allocation decisions. This panel will dive into the transformative journeys of shelved assets that have been resurrected and developed into FDA-approved treatments. Featuring expert insights from leaders who have successfully navigated the complexities of in-licensing and repositioning these drugs, the discussion will highlight strategies for identifying potential, overcoming challenges, and ultimately delivering new therapies to patients in need.
Key Discussion Points:
- Learn how companies pinpoint promising drug candidates that have been previously set aside and assess their viability for new therapeutic applications.
- Explore the processes and strategies involved in in-licensing shelved assets, including the negotiation, planning, and development stages that lead to successful outcomes.
- Gain insights into the challenges faced during the advancement of these assets, including clinical trial design, regulatory approvals, and navigating the complex landscape of drug development.
- Hear from industry leaders who have successfully brought shelved assets to market, sharing their experiences, key takeaways, and the impact these drugs have had on patients' lives.
